Traws Pharma, Inc.
TRAW
$1.68
-$0.34-16.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.77% | 3.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 81.70% | 1.83% | |||
| Operating Income | -81.70% | -224.66% | |||
| Income Before Tax | -87.86% | -333.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -87.86% | -333.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -87.86% | -333.01% | |||
| EBIT | -81.70% | -224.66% | |||
| EBITDA | -81.29% | -223.72% | |||
| EPS Basic | -67.63% | -220.39% | |||
| Normalized Basic EPS | -77.03% | -185.95% | |||
| EPS Diluted | -67.63% | -212.82% | |||
| Normalized Diluted EPS | -77.03% | -185.95% | |||
| Average Basic Shares Outstanding | 6.11% | 51.50% | |||
| Average Diluted Shares Outstanding | 6.11% | 51.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||